Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

93 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical trials of HER-2/neu-specific vaccines.
Murray JL, Przepiorka D, Ioannides CG. Murray JL, et al. Among authors: ioannides cg. Semin Oncol. 2000 Dec;27(6 Suppl 11):71-5; discussion 92-100. Semin Oncol. 2000. PMID: 11236031 Review.
Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.
Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Mine T, et al. Among authors: ioannides cg. Oncol Rep. 2010 Jun;23(6):1537-43. doi: 10.3892/or_00000793. Oncol Rep. 2010. PMID: 20428807 Free PMC article.
Short GC-rich RNA similar to miR 1909 and 1915 folds in silico with the 5'-UTR and ORF of Notch and responders: potential for the elimination of cancer stem cells.
Li Y, Mine T, Ioannides CG. Li Y, et al. Among authors: ioannides cg. Oncol Rep. 2010 Dec;24(6):1443-53. doi: 10.3892/or_00001004. Oncol Rep. 2010. PMID: 21042738
Synthetic microRNA and double-stranded RNA targeting the 3'-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells.
Tsuda N, Kawano K, Efferson CL, Ioannides CG. Tsuda N, et al. Among authors: ioannides cg. Int J Oncol. 2005 Nov;27(5):1299-306. Int J Oncol. 2005. PMID: 16211225
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S. Peoples GE, et al. Among authors: ioannides cg. Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448. Clin Cancer Res. 2008. PMID: 18245541 Clinical Trial.
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S. Peoples GE, et al. Among authors: ioannides cg. J Clin Oncol. 2005 Oct 20;23(30):7536-45. doi: 10.1200/JCO.2005.03.047. Epub 2005 Sep 12. J Clin Oncol. 2005. PMID: 16157940 Clinical Trial.
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Woll MM, et al. Among authors: ioannides cg. J Clin Immunol. 2004 Jul;24(4):449-61. doi: 10.1023/B:JOCI.0000029117.10791.98. J Clin Immunol. 2004. PMID: 15163902
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Woll MM, et al. Among authors: ioannides cg. Int J Oncol. 2004 Dec;25(6):1769-80. Int J Oncol. 2004. PMID: 15547716
Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
Efferson CL, Schickli J, Ko BK, Kawano K, Mouzi S, Palese P, GarcĂ­a-Sastre A, Ioannides CG. Efferson CL, et al. Among authors: ioannides cg. J Virol. 2003 Jul;77(13):7411-24. doi: 10.1128/jvi.77.13.7411-7424.2003. J Virol. 2003. PMID: 12805440 Free PMC article.
N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.
Matsueda S, Gao H, Efferson CL, Tsuda N, Ishiyama S, Li Y, Ioannides MG, Fisk B, Peoples GE, Ioannides CG. Matsueda S, et al. Among authors: ioannides cg. Anticancer Res. 2009 Jul;29(7):2427-35. Anticancer Res. 2009. PMID: 19596910 Free article.
93 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback